News

Number of news items returned: 141 to 160 records of 458

Funds, Introductions and Updates - Funding Strategies Connect March 2017

17 March 2017

(15199 views)

Funds, Introductions and Updates - Funding Strategies Connect March 2017 Dear Readers, It has been a busy first quarter so far with ...

Trac Group roll out of Tractile Solar Roofing gains momentum

16 March 2017

(19481 views)

  "Trac Group roll out of TractileTM Solar Roofing gains momentum   Trac Group's strategy to build a network of distributors continues to ...

QinetiQ Selects RobotEye Thermal System for Their CUAS Product Family

14 March 2017

(16224 views)

  "QinetiQ Selects RobotEye Thermal System for Their CUAS Product Family   As the use of drones proliferates, their level of sophistication increases ...

Smarter MySuper defaults

13 March 2017

(16022 views)

  Smarter MySuper defaults    "Are Super Funds being hypocritical? Telling their members who have made an investment choice and are engaged (circa 20%), ...

Queensland Business Development Fund – Co-Investor Application

10 March 2017

(16177 views)

   Queensland Business Development Fund – Co-Investor Application   "Tailored Superannuation Solutions Ltd (“TSS” or the “Company”) is pleased to confirm, following a ...

Nelson Resources appoints CPS Securities

08 March 2017

(16528 views)

  "Nelson Resources appoints CPS Securities   The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise that Nelson Resources ...

Tailored Superannuation Solutions Ltd Exceeds Minimum Subscription

22 February 2017

(16259 views)

  Tailored Superannuation Solutions Ltd Exceeds Minimum Subscription "Tailored Superannuation Solutions Ltd (“TSS” or the “Company”) is pleased to confirm that the ...

Nelson Resources extends closing of its Replacement Prospectus

22 February 2017

(16118 views)

   "Nelson Resources extends closing of its Replacement Prospectus   The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise ...

Crowdfunding and other news - Funding Strategies Connect February 2017

20 February 2017

(16586 views)

Crowdfunding and other news - Funding Strategies Connect February 2017 Dear Readers, "Crowd-sourced equity funding bill to pass Senate" It looks like Australia ...

Crowd-sourced equity funding bill to pass Senate

16 February 2017

(15311 views)

 Crowd-sourced equity funding bill to pass Senate   "Retail investors will soon be able to buy up to $10,000 of equity in ...

Trustee Tailored Super Progresses In-depth Discussions

15 February 2017

(15130 views)

  "Trustee Tailored Super Progresses In-depth Discussions" "While the company (Tailored Superannuation Solutions) is maintaining strict confidentiality around businesses they are in ...

Nelson Resources - Investor Presentation, Road Show and Extension of Offer

03 February 2017

(16547 views)

    Nelson Resources - Investor Presentation, Road Show and Extension of Offer   Nelson Resources (ASX: NES) has today released an updated investor ...

Happy new year of the Rooster - Funding Strategies Connect January 2017

20 January 2017

(16280 views)

 Happy new year of the Rooster - Funding Strategies Connect January 2017 Dear Readers, I would like to wish you a healthy, ...

Nelson Resources Lodges Replacement Prospectus

18 January 2017

(17015 views)

  "The Nelson Resources Limited Board is pleased to advise that Nelson Resources Limited has lodged its Replacement Prospectus to raise ...

Director Briefing with Douglas Bucknell from Tailored Superannuation Solutions

17 January 2017

(15878 views)

  Please read the full briefing via the link below. For more information about Tailored Superannuation Solutions Ltd, please click here.  

"Australian Army Selects Ocular Robotics’ Immersive Telepresence System to be Trialed in Army Units in 2017"

17 January 2017

(16109 views)

  "Following from Ocular Robotics initial selection to demonstrate an Immersive Telepresence System at Army Innovation Day (AID16) in October 2016, ...

Opmantek reports bumper half year result

17 January 2017

(16172 views)

 OPMANTEK REPORTS BUMPER HALF YEAR RESULT " An increase in SaaS (software as a service) subscription contracts has seen Opmantek achieve their ...

Director Briefing with Laurence Baum from BioCube

19 December 2016

(17064 views)

  Please read the full briefing via the link below. For more information about The BioCube Corporation Ltd, please click here.  

"End of year super reforms surge in preparation for 2017"

15 December 2016

(17266 views)

  "End of year super reforms surge in preparation for 2017" "In the last month, the first public skirmishes of a reform ...

"The rebirth of crowd funding in Australia!"

15 December 2016

(17181 views)

" The rebirth of crowd funding in Australia!" " Introduction In December 2015, the Corporations Amendment (Crowd-sourced Funding) Bill 2015 (2015 Bill) was ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625